Kyriakos Amarantidis
Overview
Explore the profile of Kyriakos Amarantidis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tsoulos N, Agiannitopoulos K, Potska K, Katseli A, Ntogka C, Pepe G, et al.
Cancer Genomics Proteomics
. 2024 Aug;
21(5):448-463.
PMID: 39191493
Background/aim: The application of next-generation sequencing (NGS) technology in the genetic investigation of hereditary cancer is important for clinical surveillance, therapeutic approach, and reducing the risk of developing new malignancies....
2.
Panagopoulou M, Karaglani M, Tzitzikou K, Kessari N, Arvanitidis K, Amarantidis K, et al.
Int J Mol Sci
. 2024 Apr;
25(8).
PMID: 38673785
Circulating cell-free DNA (ccfDNA) of mitochondrial origin (ccf-mtDNA) consists of a minor fraction of total ccfDNA in blood or in other biological fluids. Aberrant levels of ccf-mtDNA have been observed...
3.
Koukaki T, Balgkouranidou I, Biziota E, Karayiannakis A, Bolanaki H, Karamitrousis E, et al.
J Cancer
. 2024 Apr;
15(9):2573-2579.
PMID: 38577595
Pancreatic cancer is the most fatal cancer type in the world. Its high mortality is mostly correlated to the absence of symptoms and the difficulty in early diagnosis, which in...
4.
Ragia G, Biziota E, Koukaki T, Amarantidis K, Manolopoulos V
Pharmacogenomics
. 2024 Feb;
25(2):59-67.
PMID: 38353109
MicroRNA 27a (miR-27a) regulates post-transcriptionally DPD activity. We have analyzed the association of rs895819T>C variation, that modulates miR-27a expression, with fluropyrimidine-induced toxicity. rs895819T>C genotyping was conducted by TaqMan® allelic discrimination...
5.
Ragia G, Maslarinou A, Atzemian N, Biziota E, Koukaki T, Ioannou C, et al.
Front Pharmacol
. 2023 Oct;
14:1248898.
PMID: 37781702
Dihydropyrimidine dehydrogenase (DPD), encoded by gene, is the rate-limiting enzyme responsible for fluoropyrimidine (FP) catabolism. gene variants seriously affect DPD activity and are well validated predictors of FP-associated toxicity. variants...
6.
Ioannou C, Ragia G, Balgkouranidou I, Xenidis N, Amarantidis K, Koukaki T, et al.
Drug Metab Pers Ther
. 2022 Mar;
37(3):323-327.
PMID: 35272420
Objectives: The fluoropyrimidine derivatives 5-Fluorouracil and Capecitabine are widely used for the treatment of solid tumors. Fluoropyrimidine metabolism involves a cascade of different enzymes, including MTHFR enzyme. c.665C>T polymorphism, leading...
7.
Panagopoulou M, Cheretaki A, Karaglani M, Balgkouranidou I, Biziota E, Amarantidis K, et al.
J Clin Med
. 2021 Jul;
10(12).
PMID: 34207031
The corticotropin-releasing factor (CRF) system has been strongly associated with gastrointestinal pathophysiology, including colorectal cancer (CRC). We previously showed that altered expression of CRF receptors (CRFRs) in the colon critically...
8.
Ioannou C, Ragia G, Balgkouranidou I, Xenidis N, Amarantidis K, Koukaki T, et al.
Pharmacogenomics
. 2021 Jun;
22(11):669-680.
PMID: 34100299
gene encodes for TS enzyme involved in 5-fluorouracil (5-FU) and capecitabine (CAP) metabolism. This study assessed the association of -TSER and 3RG>C polymorphisms with 5-FU/CAP adverse event (AE) incidence. -TSER...
9.
Karamitrousis E, Balgkouranidou I, Xenidis N, Amarantidis K, Biziota E, Koukaki T, et al.
Technol Cancer Res Treat
. 2021 Apr;
20:1533033820973279.
PMID: 33928818
Epigenetic modification of several genes is a key component in the development of gastric cancer. The methylation status of , and genes was evaluated in the cell free circulating DNA...
10.
Karamitrousis E, Balgkouranidou I, Xenidis N, Amarantidis K, Biziota E, Koukaki T, et al.
Clin Chem Lab Med
. 2020 Sep;
59(2):e73-e75.
PMID: 32870805
No abstract available.